C4 Therapeutics to Present on the Discovery and Preclinical Development of CFT7455, a MonoDAC™ Degrader Targeting IKZF1/3, at the American Association for Cancer Research (AACR) Annual MeetingGlobeNewsWire • 03/10/21
C4 Therapeutics Announces FDA Clearance of Investigational New Drug Application for CFT7455, an Orally Bioavailable MonoDAC for Hematologic MalignanciesGlobeNewsWire • 01/19/21
C4 Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/07/21
C4 Therapeutics Announces Key 2021 Milestones to Support Progress Toward Goal of Four Clinical-Stage Programs by Year-End 2022GlobeNewsWire • 01/06/21
C4 Therapeutics: Preclinical Stage Protein Degrader Developer With A Differentiated ApproachSeeking Alpha • 12/27/20